The global disposable endoscopes market is expected to expand at a CAGR of 15.04% through 2035, driven by rising infection prevention initiatives, adoption of single-use endoscopes, and minimally invasive procedures. North America leads with 38.45% market share, while Asia Pacific records the fastest growth. Hospitals dominate the end-user segment with 55.36% market share, with ambulatory surgical centers showing the highest growth potential.

The global brain implants market, valued at USD 7.10 billion in 2025, is projected to reach USD 18.39 billion by 2035, growing at a CAGR of 9.99%. Growth is driven by rising prevalence of neurological disorders and increasing adoption of deep brain stimulation, neuromodulation systems, and brain-computer interfaces. North America leads the market, with the U.S. expected to grow from USD 3.16 billion to USD 8.17 billion by 2035.

The global microcatheter market is valued at USD 1.05 billion in 2025 and is projected to reach USD 1.79 billion by 2035, expanding at a CAGR of 5.53%. Growth is driven by increasing adoption of minimally invasive cardiovascular and neurovascular procedures, rising prevalence of cardiovascular and neurovascular disorders, and advancements in catheter technologies. Aspiration microcatheters lead with 36% market share, while steerable microcatheters are the fastest-growing segment. North America dominates with 34% of global revenues, with Asia-Pacific emerging as the fastest-growing region.

Boston Scientific shares have plummeted over 50% year-to-date due to repeated downward guidance revisions, particularly regarding declining Watchman procedure usage. Despite bearish market sentiment, 27 of 31 analysts maintain buy ratings with a consensus price target of $78 (65% upside), though the article cautions this recovery may be challenging without faster-than-expected growth acceleration.

The global peripheral vascular devices market is projected to grow from USD 10.02 billion in 2026 to USD 13.22 billion by 2031 at a CAGR of 5.7%, driven by rising prevalence of vascular disorders, aging populations, and innovations in minimally invasive devices. Asia Pacific is expected to see the highest growth, with major players including Boston Scientific, Medtronic, and Abbott leading the market.

Ten large-cap stocks experienced significant declines during the week of May 25-29, 2026. Zscaler led losses with a 20.06% drop following disappointing Q3 results and weak Q4 guidance. Other major losers included Boston Scientific (16.95%), AutoZone (14.21%), Regencell Bioscience (12.61%), and Venture Global (10.87%). Declines were attributed to earnings misses, analyst downgrades, and energy sector weakness following geopolitical developments.

Boston Scientific announced a $1.5 billion investment for a 34% stake in MiRus LLC, gaining entry into the transcatheter aortic valve replacement (TAVR) market projected to grow from $4.5 billion in 2024 to $12.2 billion by 2033. The deal includes an option to acquire the remaining stake for up to $3 billion if milestones are met. Wall Street remains bullish with 92% of analysts rating the stock a buy, while insider buying and a $2 billion share buyback signal management confidence.

The Dow Jones Industrial Average reached a record high above 50,600 while the Nasdaq 100 declined 0.7% on Wednesday. Oil prices fell sharply below $90 per barrel following reports of potential Iran negotiations, benefiting travel and leisure stocks. The S&P 500 edged slightly lower as semiconductor stocks retreated, while consumer discretionary and hospitality sectors led gains.

Boston Scientific reported positive pivotal trial results for its SEISMIQ 4CE Coronary Intravascular Lithotripsy catheter, meeting both primary safety and effectiveness endpoints in patients with severely calcified coronary artery disease. The trial of 420 patients achieved a 93.3% safety rate and 93.7% procedural success rate, exceeding pre-specified benchmarks. The device uses laser-generated acoustic pressure waves to fracture calcium buildup in coronary arteries before stent implantation.

Boston Scientific invested $1.5 billion in MiRus to acquire a 34% equity stake and exclusive option to acquire the SIEGEL Balloon Expandable TAVR system for treating severe aortic stenosis. The investigational device features a smaller delivery profile and advanced materials. Boston Scientific shares surged 5.56% on the announcement, though the stock remains down 42% year-to-date.

CNBC's Jim Cramer warns that while the current market is compared to the 1999 dot-com bubble, today's market is actually more brutal in punishing disappointing stocks. The market is heavily concentrated in AI and data center stocks while aggressively selling healthcare and medical technology companies that miss earnings expectations. Cramer defends AI investments as producing real business results, citing strong earnings from major tech companies.

Rosen Law Firm announces securities class action lawsuits against Boston Scientific Corporation, Camping World Holdings, Inc., and ADMA Biologics, Inc. The Boston Scientific lawsuit alleges the company made false statements about its U.S. Electrophysiology segment's sustainability while concealing material adverse facts, leading to a net income miss and underwhelming guidance. Investors who purchased shares during specified class periods are encouraged to join the litigation before upcoming deadlines.